Revlimid: Costs and the Journey of Multiple Myeloma Patients

The intense pain woke me up early one February morning in 2023. A stabbing feeling in my side was unbearable. Over weeks, a bothersome ache had grown into something more excruciating, making it hard to stand without support. Hours later in the emergency room, a doctor led me to a private area. A scan revealed concerning lesions on my hip bones and sternum—signs of multiple myeloma, a blood cancer that damages bones.

The disorder was widespread in my body, from my neck to my feet, leading to broken ribs and a spinal fracture. Without a cure, I needed fresh air and found myself sitting outside, turning to Google for answers. Online, I found outdated information, stating a three-to-five-year lifespan post-diagnosis. This made my stomach churn. Yet, newer data showed many patients living longer due, in part, to a drug with a notorious past. A doctor explained that I would likely need a thalidomide-derived drug as part of my treatment.

Thalidomide, infamous for causing severe birth defects in the 1950s and 1960s, seemed like an impossible choice. Despite its grim history, the drug had reemerged as a cancer fighter. I began taking Revlimid, a derivative of thalidomide, which has extended countless lives, including mine. Despite its success, Revlimid is extremely costly, at nearly $1,000 per daily pill. The cost to produce a capsule is just 25 cents. Its price has led to debts for some cancer patients or made them stop treatment entirely.

As a journalist, I’ve reported on inflated healthcare costs in the U.S. and the burden on patients. Revlimid’s cost stood out. Each month’s supply, received in a simple bottle, costs the same as a new car. I investigated why it was so expensive and why prices kept rising. Revlimid’s price has increased 26 times since its release. The journey to produce it involved doctors like New York City’s Beth Wolmer, whose quest began on a beach with her husband Ira, a cardiologist.

Ira developed sharp cheekbone pains, later diagnosed as multiple myeloma with a grim prognosis of two years to live. Determined to find better treatment, they met Dr. Bart Barlogie in Arkansas. Barlogie was known for trying aggressive treatments, having differences with gentler methods at his former institution. Under his care, Ira underwent intense chemotherapy and multiple transplants, all causing hair loss, weight reduction, and post-stroke complications. Despite Beth’s efforts, Ira succumbed to his illness, remembered through family photos that spurred Beth’s relentless research.

Beth reached out to Dr. Judah Folkman, who was advancing the theory of inhibiting tumor growth by blocking new blood vessel pathways. Folkman’s team, including Robert D’Amato, was searching for drugs that could achieve this in pill form. D’Amato turned to thalidomide, famous for earlier causing birth defects, lamenting that failed trials hadn’t shown promise. However, after adjusting his approach, he confirmed that thalidomide indeed blocked blood vessel growth, a revelation published in the mid-1990s.

Upon Folkman’s advice, Barlogie applied thalidomide in trials, including a patient dubbed Jimmy, who responded positively. This sparked eyes at Celgene Corp., which held thalidomide rights and pursued its potential in cancer treatment. Celgene’s losses and work on thalidomide were pivotal until thalidomide’s rebranding strategy as Thalomid boosted company sales after notable successes were reported in a 1998 conference, launching thalidomide into new fame.

Part of Revlimid’s trajectory included navigating patent complexities, needing a safer, more protected version of thalidomide. Celgene’s research and court battles for analog patents became a strategy to extend market control. Over time, Revlimid evolved into a drug with minimal competitors. Generic makers sought to test Revlimid, but Celgene’s restricted access to it stymied competitors, extending its exclusive market presence.

Even under substantial scrutiny from regulators concerned with fair competition, and despite allegations Celgene had used distribution safety programs as shields, Celgene’s pricing strategy burgeoned under burgeoning demand. As the drug’s price soared, it added to patient and insurance burdens. The cost of production remained low, yet the selling price continued increasing, benefiting executives and creating high revenue streams.

For many multiple myeloma sufferers, Revlimid means managing both disease and the staggering expense. Personal responsibilities underlined my Remission Day in November 2023 without recovery bells, realizing that treatment doesn’t solely end, but manages the illness long-term, underscoring recurrent challenges.